Citations

AbstractPatients in delirium require trustful communication and re‐orientation. We developed a flyer with positive, re‐orientating suggestions for families of delirious patients in intensive care units. Suggestions include creating a safe environment, interpreting unusual behaviours positively and fostering mental resilience. Additionally, families are encouraged to prioritize their own well‐being, recognizing their crucial role in supporting their loved ones. This flyer offers practical strategies across four key areas: ensuring security and orientation, reframing noises and body experiences, managing agitation and reshaping perceptions. By equipping families with knowledge and tools, this resource aims to promote understanding, resilience and strength to humanize delirium care.

Abstract Genome-wide association studies (GWAS) have identified over 300 loci associated with the inflammatory bowel diseases (IBD), but putative causal genes for most are unknown. We conducted the largest disease-focused expression quantitative trait loci (eQTL) analysis using colon tissue from 252 IBD patients to determine genetic effects on gene expression and potential contribution to IBD. Combined with two non-IBD colon eQTL studies, we identified 194 potential target genes for 108 GWAS loci. eQTL in IBD tissue were enriched for IBD GWAS loci colocalizations, provided novel evidence for IBD-associated genes such as ABO and TNFRSF14, and identified additional target genes compared to non-IBD tissue eQTL. IBD-associated eQTL unique to diseased tissue had distinct regulatory and functional characteristics with increased effect sizes. Together, these highlight the importance of eQTL studies in diseased tissue for understanding functional consequences of genetic variants, and elucidating molecular mechanisms and regulation of key genes involved in IBD.

6026 Background: We examined a large patient dataset based on E1305, a completed phase III randomized trial of platinum-based chemotherapy with or without bevacizumab (Argiris et al. JCO 2019), to evaluate prognostic factors in the first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RM SCCHN) and expand on our previous observations in cooperative group trials (Argiris et al. Cancer 2004). Methods: All 403 patients enrolled in E1305 were analyzed. Overall survival (OS) was the outcome of interest. Clinical and tumor characteristics were examined using Cox proportional hazards models. Variables which were significant in the univariate setting at a level of ≤ 0.10 were included in a multivariable model, and backwards selection was performed (threshold of p ≤ 0.05). The final multivariable model was then applied to the two treatment arms, separately. Variables for which the hazards ratio (HR) within an arm was more than 10% different than that for the whole cohort, were removed from the final cohort model. Results: The median OS in the whole study cohort was 11.8 months. A prognostic score model for OS was built, using the 4 independent prognostic factors identified in the multivariable model: ECOG performance status (1 vs 0), prior radiation, primary region (non-oropharynx vs oropharynx), and metastatic disease bone or liver (vs other sites/no metastases). Prognostic score was dichotomized (0-2 and > 2). Patients with 0-2 risk factors (n = 249) had a median OS of 15.2 months (90% CI: 13.8, 18.1), while patients with > 2 risk factors (n = 154) had a median OS of 7.6 months (90% CI: 6.5, 9.3); HR of 2.14 (95% CI: 1.73, 2.66), p < 0.0001. Compared to our previous 5-factor model from analysis of older trials in a similar setting, the variable “bone/liver metastasis” is new, but “tumor cell differentiation” and “weight loss” were not significant and not included in the new model for OS. Conclusions: The new proposed model includes 4 prognostic factors for OS (performance status, primary site, prior radiation, presence of bone/liver metastasis) in the first-line treatment of RM SCCHN.

6041 Background: Human papillomavirus (HPV) E6/E7 oncoproteins mediate immune evasion by down-regulating Type 1 interferons, TLR9, MHC Class I/II as well as other mechanisms, resulting in persistent infection and initiation of ̃5% of all cancers globally. Similarly, established cancers evade immune surveillance utilizing parallel mechanisms including the expression of checkpoint proteins. PDS0101 is a molecularly targeted immunotherapeutic based on an enantiospecific cationic lipid nanoparticle platform containing HPV16 neoantigens that exhibits anti-tumor activity with checkpoint inhibitors (CPIs) by upregulating Type I interferons and promoting antigen processing and cross presentation. This allows generation of high levels of polyfunctional HPV16-specific CD8 and CD4 T cells in vivo as well as immune memory. VERSATILE-002 (NCT04260126) is a phase 2 study of the combination of PDS0101 and pembrolizumab in treatment of CPI naïve and refractory patients with recurrent or metastatic HPV16-related HNSCC. Herein, we report preliminary safety and efficacy data for CPI naïve patients at a prespecified interim analysis. Methods: Subjects are treated with pembrolizumab 200mg IV every three weeks plus SC PDS0101 following pembrolizumab on days one of Cycles1-4 and Cycle12; pembrolizumab continues up until 35 cycles, disease progression or intolerance to therapy. Results: Eighteen CPI naïve subjects with confirmed HPV16 tumors and a CPS score > = 1, median age 62 yrs (range 46-71), all male, 17 (94%) of whom were White and 16 (88.9%) not Hispanic or Latino, received at least one cycle of combination therapy. At the time of analysis, 17 (94%) subjects had received > = 4 doses of PDS0101 (median 4, range 1-5) and pembrolizumab (median 7, range 1-14). There were no Grade 3 or greater treatment-related toxicities and no drug discontinuation related to toxicity or immune-related AEs. Clinical activity (CR+PR+SD) was seen in 13 (72.2%) of 18 subjects, with best overall reponse per RECIST1.1 documenting: OR in 7 (38.9%; 2 CR, 5PR); stable disease (SD) in 6 (33.3%) and progressive disease in 3 (16.7%); 2 subjects had missing data. Tumor reduction was seen in 4 of 6 (67%) subjects with SD. Nine-month PFS and OS rates (95% CI) were 52% (22.5, 74.7) and 81% (37.8, 95.5) respectively; median PFS and OS have not been reached. Conclusions: The combination of PDS0101 and pembrolizumab demonstrates an excellent safety profile with preliminary evidence of clinical activity in the majority of CPI naïve patients with HPV-related HNSCC. Clinical trial information: NCT04260126.

Abstract Background A retrospective review was performed of 15 adult patients who underwent arthroscopic suture anchor scapholunate capsuloligamentous repair between 2021 and 2023. Materials and Methods There were 12 male and 3 female patients, with a mean age of 44.9 years. Eight patients had European Wrist Arthroscopy Society (EWAS) II (Geissler II), four patients had EWAS IIIC (Geissler III), and three patients had EWAS IV (Geissler IV). After a follow-up of 12 months (12–26), the mean grip strength significantly improved by 131% compared with presurgery. There was a significant improvement in the visual analog scale score from 6 to 1.2, the Mayo Wrist Score from 43.5 to 86.5, and the Quick Disabilities of the Arm, Shoulder, and Hand questionnaire score from 65.9 to 6.5. Two EWAS IV patients had recurrent symptomatic scapholunate diastasis requiring scapholunate ligamentoplasty. Conclusion The arthroscopic dorsal scapholunate capsuloligamentous repair with suture anchors is a reliable and safe technique with minimal complications. It is recommended for reducible acute or chronic injury to the scapholunate ligament complex with suspected avulsion injury. Level of Evidence Level IV

Background: Cutaneous collagenous vasculopathy (CCV) is a rare acquired microangiopathy that commonly affects middle-aged, fair-skinned individuals. It presents with telangiectatic lesions involving the lower extremities. Histologic analysis is mandatory for diagnosis. Objectives: To describe and characterize the patients diagnosed with CCV at the Mayo Clinic. Methods: A multicenter retrospective observational analysis was performed on patients with a clinical and histological diagnosis of CCV at the Mayo Clinic in Florida, Arizona, and Rochester from January 2000 to October 2023. Results: The study included 34 patients, 22 (64.7%) females. The median age at diagnosis was 52 years (range, 12-80 years). CCV lesions were found to affect the lower extremities in 29 (85.3%) patients, followed by the trunk in 14 (41.2%). Nineteen (55.9%) patients presented 1 concomitant medical condition, 8 (23.5%) 2 conditions, and 5 (14.7%) 3 or more medical conditions, such as arterial hypertension 10 (29.4%), type 2 diabetes mellitus 3 (8.8%), hyperlipidemia 3 (8.8%), cardiac disease 3 (8.8%), and hematologic malignancy 3 (8.8%). Thirty-one patients (91.2%) were taking medications, with 19 (55.9%) taking 3 or more. Pathology staining revealed periodic acid-Schiff positivity in 23 of 34 cases (67.6%), and collagen IV in 26 of 34 cases (47.1%). Treatments included pulsed dye laser 3 (8.8%) and topical sirolimus 1 (2.9%). Conclusions: CCV is an uncommon microangiopathy that affects pediatric, middle-aged, and elderly patients. It involves the lower extremities, trunk, and upper extremities. Patients often present with associated metabolic and cardiovascular conditions and are usually taking at least 1 medication. Treatment options are limited.

Background Assessment of gastric conduit perfusion during esophagectomy is crucial to determine its viability and identify the optimal site for anastomosis. Indocyanine green (ICG) fluorescence imaging is commonly used for this purpose, but it is contraindicated in patients with hypersensitivity to ICG, iodine, or shellfish. Oxygen saturation endoscopic imaging (OXEI) is a newer, non-pharmacologic technique for assessing perfusion. We report our experience with OXEI in 3 esophagectomy patients who had contraindications to ICG. Methods All 3 patients underwent robot-assisted esophagectomies. None of the conduits had ischemic areas identified by white light. Using a 5 mm laparoscopic specialized camera (ELUXEO Vision, FUJIFILM Healthcare Americas Corp., USA), OXEI was deployed for intracorporeal assessment of gastric conduit perfusion after pull-up into the chest. Postoperative outcomes including anastomotic leaks and complications were recorded. Results In two patients, OXEI revealed ischemic zones, which were resected to ensure optimal conduit viability. In the remaining patient, OXEI indicated robust vascularity throughout the conduit. All three patients experienced uneventful postoperative courses and were discharged within 10 days. There were no instances of anastomotic leaks or other major complications. Conclusion In our experience, OXEI is a viable method for intraoperative assessment of gastric conduit perfusion in patients with contraindications to ICG. Prospective studies are needed to validate its efficacy in preventing anastomotic complications and to compare it with other methods of perfusion assessment including gross visual and ICG dye in a larger patient population.

OBJECTIVES: We aimed to summarize the most significant and impactful publications describing the pharmacotherapeutic care of critically ill patients in 2023. DATA SOURCES: PubMed/MEDLINE and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update. STUDY SELECTION: Randomized controlled trials and prospective studies of adult critically ill patients assessing a pharmacotherapeutic intervention and reporting clinical endpoints published between January 1, 2023, and December 31, 2023, were eligible for inclusion in this article. DATA EXTRACTION: Articles from a systematic search and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update were included. An a priori defined three-round modified Delphi process was employed to achieve consensus on the most impactful publications based on the following considerations: 1) overall contribution to scientific knowledge and 2) novelty to the literature. DATA SYNTHESIS: The systematic search and Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update returned a total of 1202 articles, of which 1164 were excluded. The remaining 38 articles underwent a three-round modified Delphi process. In each round, articles were independently scored based on overall contribution to scientific knowledge and novelty to the literature. Included articles are summarized and their impact discussed. Article topics included hydrocortisone for severe community-acquired pneumonia, inhaled amikacin for prevention of ventilator-associated pneumonia, methylene blue for septic shock, restrictive vs. liberal fluid management for sepsis-induced hypotension, andexanet alfa for major bleeding associated with factor Xa inhibitors, and early administration of four-factor prothrombin complex concentrate in patients with trauma at risk for massive transfusion. CONCLUSIONS: This review provides a summary and perspective on the potential impact of the most relevant articles in 2023 describing advances in the pharmacotherapeutic care of critically ill patients.

AbstractBackgroundPhoton counting detectors (PCDs) for x‐ray computed tomography (CT) are the future of CT imaging. At present, semiconductor‐based PCDs such as cadmium telluride (CdTe), cadmium zinc telluride, and silicon have been either used or investigated for clinical PCD CT. Unfortunately, all of them have the same major challenges, namely high cost and limited spectral signal‐to‐noise ratio (SNR). Recent studies showed that some high‐quality scintillators, such as lanthanum bromide doped with cerium (LaBr3:Ce), are less expensive and almost as fast as CdTe.PurposeThe objective of this study is to assess the performance of a LaBr3:Ce PCD for clinical x‐ray CT.MethodsWe performed Monte Carlo simulations and compared the performance of 3 mm thick LaBr3:Ce and 2 mm thick CdTe for PCD CT with x‐rays at 120 kVp and 20–1000 mA. The two PCDs were operated with either a threshold–subtract (TS) counting scheme or a direct energy binning (DB) counting scheme. The performance was assessed in terms of the accuracy of registered spectra, counting capability, and count‐rate‐dependent spectral imaging‐task performance, for conventional CT imaging, water–bone material decomposition, and K‐edge imaging with tungsten as the K‐edge material. The performance for these imaging‐tasks was quantified by nCRLB, that is, the Cramér–Rao lower bound on the variance of basis line‐integral estimation, normalized by the corresponding value of CdTe at 20 mA.ResultsThe spectrum recorded by CdTe was distorted significantly due to charge sharing, whereas the spectra recorded by LaBr3:Ce better matched the incident spectrum. The dead time, estimated by fitting a paralyzable detector model to the count‐rate curves, was 20.7, 15.0, 37.2, and 13.0 ns for CdTe with TS, CdTe with DB, LaBr3:Ce with TS, and LaBr3:Ce with DB, respectively. Conventional CT imaging showed an adverse effect of reduced geometrical efficiency due to optical reflectors in LaBr3:Ce PCD. The nCRLBs (a lower value indicates a better SNR) for CdTe with TS, CdTe with DB, LaBr3:Ce with TS, LaBr3:Ce with DB, and the ideal PCD, were 1.00 ± 0.01, 1.00 ± 0.01, 1.18 ± 0.02, 1.18 ± 0.02, and 0.79 ± 0.01, respectively, at 20 mA. The nCRLBs for water–bone material decomposition, in the same order, were 1.00 ± 0.02, 1.00 ± 0.02, 0.85 ± 0.02, 0.85 ± 0.02, and 0.24 ± 0.02, respectively, at 20 mA; and 0.98 ± 0.02, 0.98 ± 0.02, 1.09 ± 0.02, 0.83 ± 0.02, and 0.24 ± 0.02, respectively, at 1000 mA. Finally, the nCRLBs for K‐edge imaging, the most demanding task among the five, were 1.00 ± 0.02, 1.00 ± 0.02, 0.55 ± 0.02, 0.55 ± 0.02, and 0.13 ± 0.02, respectively, at 20 mA; and 2.45 ± 0.02, 2.29 ± 0.02, 3.12 ± 0.02, 2.11 ± 0.02, and 0.13 ± 0.02, respectively, at 1,000 mA.ConclusionThe Monte Carlo simulations showed that, compared to CdTe with either TS or DB, LaBr3:Ce with DB provided more accurate spectra, comparable or better counting capability, and superior spectral imaging‐task performances, that is, water–bone material decomposition and K‐edge imaging. CdTe had a better performance than LaBr3:Ce for the conventional CT imaging task due to its higher geometrical efficiency. LaBr3:Ce PCD with DB scheme may be an excellent alternative option for CdTe PCD.